Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210855 | 0.79 | ALDH1A1 (0.39) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| Hydrochloric Acid SCHEMBL1246276 | 0.78 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| SCHEMBL4887318 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HPGDACHETDP1HSD17B10 | |
| Bromide SCHEMBL8665049 | 0.76 | ALDH1A1 (0.37) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| SCHEMBL4014123 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| SCHEMBL4299906 | 0.74 | ALDH1A1 (0.70) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| SCHEMBL4014126 | 0.72 | KMT2A (0.64) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| Acridine SCHEMBL27603600 | 0.71 | ALDH1A1 (0.94) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| SCHEMBL27701955 | 0.70 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4EGLAKMT2A | |
| SCHEMBL30857473 | 0.70 | ALDH1A1 (0.64) | ALDH1A1HPGDKDM4EGLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257538-B1 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-1261325-B1 | TUMOR INHIBITING COMPOSITIONS COMPRISING NITROACRIDINES | NEW YORK MEDICAL COLLEGE (US) | 2010-09-08 | — | — | EP | disclosed |
| US-7622478-B2 | 1-nitroacridine/tumor inhibitor compositions | TIWARI RAJ | 2009-11-24 | — | — | US | disclosed |
| US-6589961-B2 | For inhibiting metastases of a tumor in a mammal | NEW YORK MEDICAL COLLEGE | 2003-07-08 | — | — | US | disclosed |
| EP-1261325-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1257538-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NEW YORK MEDICAL COLLEGE | 2002-07-25 | — | — | US | disclosed |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | TIWARI RAJ (US) | 2002-03-28 | — | — | US | disclosed |
| WO-2001060801-A2 | 9-ALKYLAMINO-1-NITROACRIDINE DERIVATIVES | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001060351-A2 | NITROACRIDINE/TUMOR INHIBITOR COMPOSITIONS | NEW YORK MEDICAL COLLEGE (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099211-A1 | 9-alkylamino-1-nitroacridine derivatives | NPPA, ABCB11, ABCC9 | ALDH1A1 82/4885HPGD 141/4885KDM4E 4417/4885 |
| US-20020037831-A1 | 1-Nitroacridine/tumor inhibitor compositions | MKI67, DIAPH1, API5 | ALDH1A1 139/4885HPGD 94/4885KDM4E 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.